Welcome Arne Smits

Arne has a PhD degree from the Radboud University (Nijmegen, The Netherlands). His previous research in the laboratory of Prof. Michiel Vermeulen focused on the identification and quantification of protein-protein and DNA-protein interactions using quantitative proteomics. As a EIPOD postdoctoral fellow at EMBL, he is studying the systems-wide effects of drug treatment in collaboration with Cellzome and the Steinmetz group.

Congratulations Sophie Rabe

Sophie studied Molecular Biotechnology at the University of Heidelberg. She joined the Huber Group in Spring 2014 as student research assistant and worked on genomic biomarkers of drug sensitivity in primary blood cancer cells. For her PhD thesis, Sophie is now joining the group of Sascha Dietrich at NCT Heidelberg, where she will work on the SYMPATHY project, an integrated system medicine approach to personalized and targeted therapy in leukaemia and lymphoma. This multidisciplinary project is intended to have direct clinical impact on patient care in blood cancers.

Welcome Karsten Bach

Karsten Bach has a B.Sc. in Biology from the University of Bonn. He joined the Huber group in March 2016. At EMBL, he is finishing up his M.Sc. in Molecular Biotechnology and working on quantitative proteomics together with Dorothee Childs and Nikos Ignatiadis.

Presentation by Dorothee

Dorothee Childs presented her work at the EMBL-Wellcome Genome Campus Conference “Target Validation using Genomics and Informatics 2015″, which took place from 8th to 10th December 2015 in Cambridge.
More than 200 people attended this ground-breaking conference. Dorothee gave a talk on “Screening for drug targets in intact cells by thermal proteome profiling”, a project in which she is involved as part of a collaboration between EMBL Heidelberg and GSK’s SME Cellzome, which is also based in Heidelberg.”

thumb_IMG_0110_1024

thumb_IMG_0102_1024 2

thumb_IMG_0109_1024

Welcome Annika

Annika Gable has a B.Sc. in Molecular Biotechnology from the University of Heidelberg. She joined the Huber group in December 2015. At EMBL, she is finishing up her M.Sc. in Molecular Biotechnology (major: Bioinformatics) with a thesis on analyzing high-throughput chromatin conformation capture (Hi-C) data.

Welcome Junyan Lu

Junyan has a PhD in Computational Biology and Drug Design from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. His previous research focused on understanding mechanisms of drug response using integrated multi-omics technology and large scale ex-vivo drug testing approaches. In November 2015, he joined the Huber Group as a postdoctoral fellow and is now working on the SOUND project.

Welcome Mike Smith

Mike joined EMBL in October 2015 as part of the de.NBI project where he is working on the development pipelines, workflows and computational approaches for large scale biological experiments. He has a PhD in computational biology from the University of Cambridge, UK.

Read more